Casdin Capital, LLC Crispr Therapeutics Ag Transaction History

Casdin Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$53.19 - $79.24 $14.2 Million - $21.1 Million	-266,430 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$33.68 - $62.53 $8.97 Million - $16.7 Million	266,430 New	266,430 $11.3 Million
Q4 2018 Feb 13, 2019	SELL	$22.73 - $42.34 $5 Million - $9.31 Million	-220,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$42.62 - $73.59 $3.62 Million - $6.26 Million	85,000 Added 62.96%	220,000 $12.9 Million
Q1 2018 May 15, 2018	BUY	$23.52 - $58.17 $3.18 Million - $7.85 Million	135,000 New	135,000 $6.17 Million

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.15B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Casdin Capital, LLC with notifications on news.